GENF (GENF) News
Follow GENF (GENF) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Genflow Biosciences PLC (GENF) Raises £0.31M From Warrant Exercises
Genflow received warrant exercises for 28,124,999 new shares at 1.1p, raising £309,375. Admission of the shares to the LSE main market is expected on Oct 2, 2026, taking total voting rights to 594,534,781.Material Detail
EQUITY | Sep 29, 2026, 01:38 PM UTC
L
Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUB
NEWS | Sep 29, 2026, 01:38 PM UTC
L
Genflow Biosciences Plc (GENF) Posts H1 2026 Report, Cash £632.6K After £1.15M Raise
Genflow Biosciences Plc reported unaudited H1 2026 results: cash £632,553 at 30 Jun 2026 after £1,148,875 net equity raise; admin expenses £454,311. SLAB canine trial completed; full results to be presented Oct 2, 2026.M
NEWS | Sep 29, 2026, 06:01 AM UTC
L
Genflow Biosciences PLC Announces Half-year Financial Report
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT
NEWS | Sep 29, 2026, 06:01 AM UTC
M
Genflow Biosciences says Slab clinical trial meets primary endpoint
Genflow Biosciences PLC says its Slab clinical trial met the primary endpoint.
EQUITY | Sep 08, 2026, 06:51 AM UTC
M
Genflow Biosciences reports primary endpoint in SLAB clinical trial
Genflow Biosciences PLC said it has a primary endpoint in its SLAB clinical trial, in an RNS published 08 September 2026.
EQUITY | Sep 08, 2026, 06:00 AM UTC
L
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT
EQUITY | Sep 08, 2026, 06:00 AM UTC
L
Genflow Biosciences appoints ON365 as investor relations adviser
Genflow Biosciences PLC appointed ON365 Partners Inc. as its investor relations adviser, effective for company IR activities.
EQUITY | Sep 07, 2026, 06:00 AM UTC